Ondansetron (Zofran) is a 5-HT3 serotonin receptor antagonist antiemetic used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It is also widely used off-label for severe nausea in pregnancy. It works by blocking serotonin receptors in the gut and brain that trigger the vomiting reflex. Key risks include QT interval prolongation at higher doses, constipation, and an FDA warning about first-trimester pregnancy use due to a potential small risk of congenital malformations.
Ondansetron
Uses & FDA Indications
Ondansetron is FDA-approved for the prevention and treatment of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, prevention of post-operative nausea and vomiting (PONV), and prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction, or daily fractions to the abdomen.
Among its most common off-label uses is the management of nausea and vomiting in pregnancy, particularly hyperemesis gravidarum — severe nausea and vomiting that can lead to dehydration and hospitalization. In this context it is typically considered after first-line treatments (vitamin B6, doxylamine) have proven inadequate.
Gastroenteritis-related nausea and vomiting, particularly in pediatric emergency settings, represents another frequent off-label application, where ondansetron's oral dissolving tablet (ODT) formulation is especially practical for patients who cannot reliably swallow oral medications.
How It Works
Ondansetron is a selective antagonist at 5-HT3 serotonin receptors. Serotonin is released from enterochromaffin cells in the gut in response to emetogenic stimuli — cytotoxic chemotherapy agents, radiation, and surgical stress. This serotonin activates 5-HT3 receptors on vagal afferent neurons, sending signals to the vomiting center in the brainstem (area postrema and nucleus tractus solitarius).
By blocking 5-HT3 receptors both peripherally (in the gastrointestinal tract) and centrally (in the chemoreceptor trigger zone of the area postrema), ondansetron interrupts the afferent signaling pathway that initiates the vomiting reflex. This dual peripheral and central mechanism accounts for its efficacy across diverse emetogenic contexts.
The orally disintegrating tablet (ODT) formulation of ondansetron dissolves on the tongue within seconds without water — a practical advantage for nauseated patients who may struggle to swallow conventional tablets. Despite dissolving in the mouth, ondansetron ODT is still absorbed systemically through the gastrointestinal tract; it does not have a meaningfully faster onset than the standard tablet formulation.
FDA WARNING — PREGNANCY: The FDA has issued a safety communication regarding ondansetron use during the first trimester of pregnancy. Epidemiological studies have raised concerns about a small increased risk of oral clefts (cleft palate) and cardiac septal defects. Ondansetron is not FDA-approved for use in pregnancy and should only be used when potential benefits outweigh risks after discussion with a healthcare provider.
Side Effects
Common
- Headache — the most commonly reported adverse effect, occurring in a significant proportion of patients
- Constipation — due to blockade of 5-HT3 receptors in the gut, which reduces intestinal motility; can be pronounced with repeated use
- Dizziness
- Fatigue, malaise
- Transient elevation of liver enzymes — usually mild and reversible
Serious
- QT prolongation and cardiac arrhythmias — dose-dependent prolongation of the QTc interval; risk of torsades de pointes, particularly with IV administration at higher doses or when combined with other QT-prolonging drugs
- Serotonin syndrome — rare, but possible when ondansetron is used with other serotonergic drugs; presents as agitation, tremor, hyperthermia, and autonomic instability
- Hypersensitivity reactions — including anaphylaxis and bronchospasm, particularly with IV formulations
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| QT-Prolonging Drugs (antipsychotics, fluoroquinolones, methadone, hydroxyzine) | Additive QTc prolongation, raising risk of torsades de pointes ventricular arrhythmia. Risk increases with IV ondansetron at higher doses. | High — review cardiac risk; obtain baseline ECG if multiple QT-prolonging agents required |
| Serotonergic Drugs (SSRIs, SNRIs, tramadol, lithium, fentanyl) | Possible serotonin syndrome. Ondansetron's 5-HT3 antagonism may partially mitigate risk but does not eliminate it — concurrent serotonin excess from other pathways can still occur. | Moderate — monitor for serotonin syndrome symptoms: agitation, tremor, fever, tachycardia |
| Apomorphine | Severe hypotension and loss of consciousness have been reported with concurrent use. Combination is contraindicated. | Contraindicated |
| CYP3A4 / CYP1A2 Inhibitors (fluconazole, ciprofloxacin) | Reduced ondansetron metabolism, leading to increased blood levels and elevated QT risk. | Moderate — monitor QTc; consider dose reduction if clinically appropriate |
Warnings & Contraindications
Contraindications
- Concomitant use of apomorphine — risk of severe hypotension
- Known hypersensitivity to ondansetron or other 5-HT3 receptor antagonists
QT Prolongation
The FDA has issued safety communications about dose-dependent QT interval prolongation with ondansetron. The 32 mg IV single-dose formulation was withdrawn from the market due to this risk. Patients with hypokalemia, hypomagnesemia, congenital long QT syndrome, or those taking other QT-prolonging medications are at elevated risk. Intravenous ondansetron should be administered slowly and at the lowest effective dose.
Hepatic Impairment
Ondansetron is extensively metabolized in the liver. In patients with severe hepatic impairment (Child-Pugh Class C), clearance is substantially reduced and plasma levels increase significantly. Total daily dose limits apply in this population — clinicians should consult current prescribing information for hepatic impairment dosing guidance.
Check for QT prolongation risk or serotonin syndrome risk with ondansetron.
Check Drug Interactions →Frequently Asked Questions
Is ondansetron safe during pregnancy?
The FDA has issued a warning regarding ondansetron use in the first trimester of pregnancy. Some studies suggest a small increased risk of cleft palate and cardiac septal defects with first-trimester exposure, though evidence remains mixed. It is widely used off-label for hyperemesis gravidarum (severe nausea and vomiting in pregnancy) when other treatments fail, particularly in the second and third trimesters. The decision to use ondansetron during pregnancy should involve a careful risk-benefit discussion with a healthcare provider.
Can ondansetron cause constipation?
Yes. Constipation is one of the most commonly reported side effects of ondansetron. Serotonin plays an important role in stimulating intestinal motility, and blocking 5-HT3 receptors in the gut slows gastrointestinal transit. This effect is dose-related and can be significant, particularly with repeated or prolonged use. Patients should maintain adequate hydration and dietary fiber while taking ondansetron.
Does ondansetron interact with other medications?
Yes. Ondansetron has several clinically important interactions. The most serious involves QT prolongation: combining ondansetron with other QT-prolonging drugs substantially raises the risk of dangerous cardiac arrhythmias. Ondansetron is also metabolized by CYP3A4 and CYP1A2 enzymes, so drugs that inhibit or induce these pathways can alter its blood levels. Serotonergic drugs used concurrently may increase serotonin syndrome risk, and concurrent apomorphine is contraindicated due to severe hypotension risk.